The Longevity Investor Network (LIN) is a global initiative convened by the Lifespan Research Institute to catalyze private investment in biotechnology companies developing interventions that target the root mechanisms of aging. By mobilizing capital and fostering investor education, LIN supports the translation of cutting-edge science into therapies that extend human healthspan.
The network supports a diverse pipeline of companies addressing areas such as tissue regeneration, cellular reprogramming, senescence clearance, metabolic and mitochondrial health, neurodegeneration, and immune system rejuvenation.
Since its founding in 2020, the LIN has deployed over $5.5 million into promising biotechnology ventures and has grown into a trusted hub for longevity-focused deal flow and investor collaboration.
A Program of Lifespan Research Institute
As a program of the Lifespan Research Institute, a nonprofit dedicated to advancing translational longevity science, the LIN reflects LRI’s commitment to accelerating real-world impact. Together, LRI and the LIN work to ensure that scientific breakthroughs in aging biology are not left on the shelf, but are actively translated into next-generation therapies for human benefit.
Interested in Pitching to the Longevity Investor Network?